Practical reading from Professor Paul Lee and the Lincolnshire Hip Clinic team — across hip replacement, Arthrosamid, ChondroFiller, PRP and the wider world of hip and groin pain.
Hip cartilage lacks blood supply and cannot repair itself; ChondroFiller injection, an outpatient collagen scaffold, achieves functional improvements comparable to surgical repair whilst carrying substantially lower procedural risk (0–8% versus 30–37% reoperation rates).
Hip osteoarthritis most commonly begins with a deep groin ache — not the outer hip pain many expect — and morning stiffness; because cartilage damage produces no pain signal, the disease often progresses substantially before symptoms demand attention.
A collagen scaffold injected under ultrasound guidance self-sets and bonds with the hip joint within minutes, then is gradually replaced by the patient's own regenerated cartilage over twelve to twenty-four months; high-impact activity typically becomes safe at the ten to twelve-month mark.
Adult hip cartilage cannot self-repair because it lacks blood supply — no circulating stem cells can reach damaged tissue after growth plates close. ChondroFiller injection is a collagen scaffold that enables the body's own progenitor cells to migrate in, populate, and remodel the defect.
ChondroFiller delivers acellular collagen into focal cartilage voids to scaffold cell recruitment and repair, whilst PRP concentrates growth factors to reduce inflammation across diffuse degeneration—two distinct mechanisms for two distinct problems.
ChondroFiller is an acellular collagen scaffold that recruits the body's own cells to repair focal cartilage damage. Advanced hip osteoarthritis is the single biggest exclusion because the scaffold depends on intact surrounding cartilage to anchor itself — tissue that the disease has already degraded.
Landmark-guided hip injections achieve intra-articular accuracy of 60–80%; ultrasound guidance exceeds 95%. For ChondroFiller—a collagen scaffold that must contact the cartilage defect directly—missing the target is not a partial problem but treatment failure.
Microfracture clots are mechanically fragile and fail in over 40% of patients within three years; AMIC prevents this by securing a dissolvable collagen membrane over the defect, protecting repair tissue for focal hip cartilage lesions 2–8 cm² in patients aged 18–50.
ChondroFiller injection places a collagen scaffold directly over diffuse hip wear, recruiting the body's repair cells to remodel it into fibrocartilage—a structural approach distinct from the lubricating injections that precede it.
Lincolnshire Hip Clinic
Led by Professor Paul Lee
Start with a free, non-medical discovery call with our team. We will tell you, honestly, which of our pathways — surgical or non-surgical — fits your situation. No GP referral, no pressure to proceed.
What we offer
